Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter can be downloaded here. It is a non-diversified fund that focuses on long-term capital appreciation by investing in common stocks of U.S. and non-U.S. companies. In the second quarter, the fund (Investor Class) delivered a return of 7.89%, lagging the benchmark, the MSCI World Index’s 13.76% return. Energy and industrials were the top performance contributors at the sector level, while health care and consumer discretionary detracted from performance. AI remains a key market theme. The firm focuses on evaluating companies based on their competitive advantages, long-term cash flow potential, and valuation, not predictions. In addition, you can check the Fund’s top five holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, Oakmark Global Fund highlighted AstraZeneca PLC (NYSE:AZN) as a newly added position. AstraZeneca PLC (NYSE:AZN) is a leading multinational biopharmaceutical company focusing on the development and discovery of prescription medicines. On July 15, 2026, AstraZeneca PLC (NYSE:AZN) closed at $168.37 per share, reflecting a market capitalization of $261.12 billion. AstraZeneca PLC (NYSE:AZN) posted a one-month return of -3.75%, while its shares gained 18.55% over the past 52 weeks.
Oakmark Global Fund stated the following regarding AstraZeneca PLC (NYSE:AZN) in its Q2 2026 investor update:
“AstraZeneca PLC (NYSE:AZN) is one of the largest pharmaceutical companies in the world. It researches, develops and commercializes prescription medicines designed to treat lung and breast cancers, cardiorenal diseases, respiratory problems and other rare diseases. We believe AstraZeneca’s robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team. In our view, CEO Pascal Soriot is one of the industry’s best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come, in our view. Recent concerns over United States regulations have overshadowed AstraZeneca’s merits and weighed on the broader pharmaceutical industry. This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value.”
AstraZeneca PLC (NYSE:AZN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 57 hedge fund portfolios held AstraZeneca PLC (NYSE:AZN) at the end of the first quarter, up from 56 in the previous quarter. While we acknowledge the risk and potential of AstraZeneca PLC (NYSE:AZN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AstraZeneca PLC (NYSE:AZN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered AstraZeneca PLC (NYSE:AZN) and shared the list of best weight loss drug stocks to buy in 2026. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
